DDW 2019—Endoscopic retrograde cholangiopancreatography safe in kids


  • Sean Henahan
  • Conference Reports
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Endoscopic retrograde cholangiopancreatography (ERCP) is safe and provides clinically useful diagnostic information in the pediatric patient population.

Why this matters

  • ERCP is an endoscopic diagnostic procedure used every day in adult populations to evaluate the pancreatic and bile ducts.
  • Little data from clinical trials have been available for ERCP in the pediatric population.
  • This is the first multicenter, prospective study of its kind.

Study design

  • Multicenter prospective study including participation of 15 IRB approved clinics.
  • The study evaluated 1124 ERCP procedures in 857 consecutive patients
  • 803 (71.2%) procedures were performed on a native papilla.
  • The mean age was 12.1 years, with only 5% of procedures performed on patients younger than 3 years of age.
  • Adverse events were described using the American Society of Gastrointestinal Endoscopy lexicon.

Key results

  • Biliary indications were most common, accounting for 76.4% of cases. Pancreatic indications accounted for 27.6% of cases.
  • Overall technical success was achieved in 1017 (90.5%) cases.
  • Adverse events were documented in 107 (9.5%) cases.
  • Post-ERCP pancreatitis was the most common adverse event, occurring in 5% of cases, similar to what is seen in adult populations.